Analysts’ Weekly Ratings Updates for Femasys (FEMY)

A number of research firms have changed their ratings and price targets for Femasys (NASDAQ: FEMY):

• 8/22/2026 – Femasys was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/18/2026 – Femasys had its price target lowered by Lake Street Capital to $10.00. They now have a “buy” rating on the stock.
• 8/17/2026 – Femasys was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/14/2026 – Femasys had its price target lowered by Maxim Group to $10.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Femasys was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/16/2026 – Femasys was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Activity

In related news, CEO Kathy Lee-Sepsick purchased 15,625 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, with a total value of $50,000.00. Following the transaction, the chief executive officer owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dov Elefant acquired 15,625 shares of the business’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the transaction, the chief financial officer owned 15,625 shares of the company’s stock, valued at approximately $50,000. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 38,750 shares of company stock worth $124,000. Company insiders own 7.75% of the company’s stock.

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.